SAN DIEGO--(BUSINESS WIRE)--SynteractHCR, a full-service, international contract research organization (CRO), will participate in the Drug Information Association (DIA) 2016 52nd Annual Meeting, which runs from June 26-30 at the Philadelphia Convention Center. The company will exhibit in booth #917. In addition, Dr. Stephan de la Motte, the company’s chief medical advisor, will participate in a panel discussion on “Rare Disease Clinical Trials: Coping with Unique Challenges” on Monday, June 27 at 8:30 a.m.
As the complexity of clinical trials continues to ramp up, SynteractHCR’s overarching focus for DIA 2016 is on providing “expertise to guide your most complex trials to confident results.” SynteractHCR’s experts are prepared to discuss how the company’s consultative approach and full service offering address the needs of innovative drug and device developers regarding:
- The new EU Clinical Trial Regulation being implemented
- Regulations surrounding pediatric trials
- Special considerations for orphan and rare disease trials
- The core challenges and solutions for immunotherapy research.
During Dr. de la Motte’s presentation, panelists will address:
- An overview of the rare disease clinical environment
- Operational metrics with respect to start-up and recruitment
- Core challenges and creative methods for overcoming these hurdles
- Rare disease in-depth case study involving Latin America and pediatric patients
Recently, SynteractHCR announced transition of ownership to Amulet Capital Partners, a private equity investment firm focused exclusively on the healthcare sector. “In this dynamic industry, a clear imperative for SynteractHCR is to sustain our growth and advance our capabilities to continue meeting the needs of our clients,” says SynteractHCR CEO Wendel Barr. “Our recent acquisition by Amulet gives us renewed vigor around investment in tools, processes and people to help in our day to day work; a focus on hiring more impact players; and, the opportunity to benefit from new energy Amulet brings as investment partners who understand the challenges and complexities of what we do to support our clients. During DIA 2016, we look forward to engaging with our colleagues and clients, to better understand how we can apply our expertise to bring success to their complex trials.”
SynteractHCR will have its own team of recruitment professionals available to discuss global career opportunities within the company, particularly in the areas of clinical operations, biostatistics and safety.
Sponsors interested in setting a private appointment, please contact Executive Director of Business Development Kim Martinez at 760-529-3440 or email@example.com.
SynteractHCR will post live updates from DIA on Twitter @SynteractHCR. Visit global-cro.synteracthcr.com/dia2016 for more information and to sign up to receive informative handouts.
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.